DE69939036D1 - PEG Konjugate von LHRH Analogen - Google Patents

PEG Konjugate von LHRH Analogen

Info

Publication number
DE69939036D1
DE69939036D1 DE69939036T DE69939036T DE69939036D1 DE 69939036 D1 DE69939036 D1 DE 69939036D1 DE 69939036 T DE69939036 T DE 69939036T DE 69939036 T DE69939036 T DE 69939036T DE 69939036 D1 DE69939036 D1 DE 69939036D1
Authority
DE
Germany
Prior art keywords
peg conjugates
lhrh analogs
conjugates
lhrh analog
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69939036T
Other languages
English (en)
Inventor
Tayar Nabil El
Xuan Zhao
Michael D Bentley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Laboratoires Serono SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Serono SA filed Critical Laboratoires Serono SA
Application granted granted Critical
Publication of DE69939036D1 publication Critical patent/DE69939036D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69939036T 1998-04-28 1999-04-28 PEG Konjugate von LHRH Analogen Expired - Fee Related DE69939036D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8334098P 1998-04-28 1998-04-28

Publications (1)

Publication Number Publication Date
DE69939036D1 true DE69939036D1 (de) 2008-08-14

Family

ID=22177691

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69925830T Expired - Fee Related DE69925830T2 (de) 1998-04-28 1999-04-28 Peg-lhrh analog konjugate
DE69939036T Expired - Fee Related DE69939036D1 (de) 1998-04-28 1999-04-28 PEG Konjugate von LHRH Analogen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69925830T Expired - Fee Related DE69925830T2 (de) 1998-04-28 1999-04-28 Peg-lhrh analog konjugate

Country Status (12)

Country Link
US (2) US6433135B1 (de)
EP (1) EP1075282B1 (de)
JP (1) JP2002512982A (de)
AT (2) ATE297762T1 (de)
AU (1) AU760381B2 (de)
CA (1) CA2330448A1 (de)
DE (2) DE69925830T2 (de)
DK (1) DK1075282T3 (de)
ES (2) ES2242396T3 (de)
IL (2) IL139285A0 (de)
PT (1) PT1075282E (de)
WO (1) WO1999055376A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ334068A (en) * 1997-06-06 2000-07-28 Kyowa Hakko Kogyo Kk Polypeptides chemically modified with polyalkylene glycol derivatives
SI2319928T1 (sl) * 1998-10-23 2013-08-30 Kirin-Amgen, Inc. Dimerni trombopoietinski peptidni mimetiki, ki se veĺ˝ejo na receptor mp1 in imajo trombopoietinsko aktivnost
NZ512581A (en) 1999-01-08 2002-12-20 Univ Virginia Commonwealth Polymeric delivery agents comprising a polymer conjugated to a modified amino acid and derivatives thereof
JP4027663B2 (ja) * 1999-10-04 2007-12-26 ネクター セラピューティックス エイエル，コーポレイション ポリマー安定化神経ペプチド
AR030631A1 (es) * 2000-09-29 2003-08-27 Abbott Lab Polipeptidos antiangiogenicos y metodos para inhibir la angiogenesis
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
WO2004099231A2 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
GB0202906D0 (en) 2002-02-07 2002-03-27 Univ London Prevention of myocardial damage
WO2004062574A2 (en) * 2003-01-13 2004-07-29 Bracco Imaging S.P.A. Improved linkers for radiopharmaceutical compounds
NZ542094A (en) * 2003-03-14 2008-12-24 Neose Technologies Inc Branched polymer conjugates comprising a peptide and water-soluble polymer chains
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
WO2006127896A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US20050054752A1 (en) * 2003-09-08 2005-03-10 O'brien John P. Peptide-based diblock and triblock dispersants and diblock polymers
CN1867581B (zh) 2003-10-10 2012-02-01 诺沃挪第克公司 Il-21衍生物
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
CN101072789B (zh) 2004-01-08 2013-05-15 生物种属学股份公司 肽的o-连接的糖基化
JP2008505928A (ja) * 2004-07-08 2008-02-28 アムジェン　インコーポレーテッド 治療用ペプチド
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
EP1799249A2 (de) 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegyliertes interferon alpha
EP1814573B1 (de) 2004-10-29 2016-03-09 ratiopharm GmbH Remodellierung und glykopegylierung von fibroblasten-wachstumsfaktor (fgf)
MX2007007580A (es) * 2004-12-22 2007-12-11 Ambrx Inc Hormona del crecimiento humana modificada.
CA2593682C (en) 2005-01-10 2016-03-22 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
JP4877225B2 (ja) * 2005-02-18 2012-02-15 日油株式会社 ポリオキシアルキレン誘導体
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
US20070238656A1 (en) * 2006-04-10 2007-10-11 Eastman Kodak Company Functionalized poly(ethylene glycol)
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
JP2009544327A (ja) 2006-07-21 2009-12-17 ノヴォ ノルディスク アー／エス Ｏ−結合型グリコシル化配列によるペプチドのグリコシル化
EP2054521A4 (de) 2006-10-03 2012-12-19 Novo Nordisk As Verfahren zur reinigung von polypeptid-konjugate
KR20150064246A (ko) 2007-04-03 2015-06-10 바이오제너릭스 게엠베하 글리코페길화 ｇ―ｃｓｆ를 이용하는 치료 방법
ES2551123T3 (es) 2007-06-12 2015-11-16 Ratiopharm Gmbh Proceso mejorado para la producción de azúcares de nucleótido
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
WO2009075788A1 (en) * 2007-12-05 2009-06-18 Semprus Biociences Corporation Synthetic non-fouling amino acids
CN101965200B (zh) 2008-02-27 2013-06-19 诺沃-诺迪斯克有限公司 缀合的因子ⅷ分子
US10166295B2 (en) 2011-06-02 2019-01-01 Opko Biologics Ltd. Pegylated OXM variants
US8383093B1 (en) 2011-11-01 2013-02-26 Serina Therapeutics, Inc. Subcutaneous delivery of poly(oxazoline) conjugates
JP6290193B2 (ja) 2012-06-04 2018-03-07 オプコ バイオロジクス リミテッド ペグ化ｏｘｍ変異体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935491A (en) 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
JPH03148298A (ja) * 1989-11-01 1991-06-25 Sumitomo Pharmaceut Co Ltd 修飾ペプチドおよびその製造方法
AU5006993A (en) * 1992-08-21 1994-03-15 Enzon, Inc. Novel attachment of polyalkylene oxides to bio-effecting substances
US5449720A (en) * 1993-05-24 1995-09-12 Biotech Australia Pty Limited Amplification of the VB12 uptake system using polymers
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US7953788B2 (en) * 2001-09-29 2011-05-31 Siebel Systems, Inc. System and method for queuing data for an application server

Also Published As

Publication number Publication date
US6433135B1 (en) 2002-08-13
DE69925830D1 (de) 2005-07-21
EP1075282B1 (de) 2005-06-15
IL139285A (en) 2007-03-08
ES2242396T3 (es) 2005-11-01
DK1075282T3 (da) 2005-10-10
AU760381B2 (en) 2003-05-15
DE69925830T2 (de) 2006-05-04
CA2330448A1 (en) 1999-11-04
JP2002512982A (ja) 2002-05-08
AU3869699A (en) 1999-11-16
ATE297762T1 (de) 2005-07-15
WO1999055376A1 (en) 1999-11-04
ATE399567T1 (de) 2008-07-15
EP1075282A1 (de) 2001-02-14
US7268210B2 (en) 2007-09-11
US20050222214A1 (en) 2005-10-06
ES2309618T3 (es) 2008-12-16
IL139285A0 (en) 2001-11-25
PT1075282E (pt) 2005-09-30

Similar Documents

Publication Publication Date Title
DE69939036D1 (de) PEG Konjugate von LHRH Analogen
FI963103A0 (fi) Ei-virusvektori
DE69713526D1 (de) Lösliche prodrugs von paclitaxel
AP2001002187A0 (en) Piperidines as CCR5 modulators.
HUP0100507A2 (hu) Polietilén-glikol-GRF konjugátumok, eljárás azok helyspecifikus előállítására, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
AP9701019A0 (en) Phenylamino-substituted tricycle derivatives.
RS49756B (sr) Primena ksenona ili smeša ksenonskog gasa za proizvodnju farmaceutskog preparata za lečenje neurointoksikacija
DE68903846D1 (de) Neue galenische form von fenofibrat.
WO2000066175A3 (en) Conjugates as therapies for cancer and prostate diseases
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
LU91281I2 (fr) Preotact-hormone parathyroïde
ATE433959T1 (de) Analoge von kokain
EP0896533A4 (de) Pentafluorobenzensulfonamiden und analoge
DE3650358T2 (de) Diphosphonate enthaltende pharmazeutische Zusammensetzungen zur Behandlung von Arthrosis.
PT998287E (pt) Utilizacao de levobupivacaina
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
HUP9802206A1 (hu) Thalidomid intravénás adagolási formája immunológiai megbetegedések gyógyításához
DE69625682D1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
NO995481L (no) Glykokonjugater av 20 (S)-camptothecin
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
TR200101366T2 (tr) Farmasötik kompozisyonların muhtevasında bulunan bazı substitüte kaprolaktamlar ve tümör tedavisinde kullanımları.
ATE203665T1 (de) Stabilisierte pharmazeutische zusammensetzungen und verfahren zu ihrer herstellung
PT1066304E (pt) Antagonistas macrolidos de lhrh
FR2701952B1 (fr) Nouveaux dérivés cyclopeptidiques de l'angiopeptine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
HUP9904578A2 (hu) Xanomelin alkalmazása bipoláris depresszió kezelésére szolgáló gyógyszerkészítmények előállítására

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee